Skip to main content

Table 3 Risk of ESRD and all-cause mortality by HDL-C category and each 0.1 mmol increase of HDL-C

From: Effect of low and high HDL-C levels on the prognosis of lupus nephritis patients: a prospective cohort study

 

Model 1

Model 2

Model 3

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

ESRD

 Low HDL-C

1.01 (0.61, 1.68)

0.958

0.93 (0.48, 1.80)

0.828a

0.93 (0.46, 1.90)

0.847

 Intermediate HDL-C

Ref

–

Ref

–

Ref

–

 High HDL-C

0.64 (0.29, 1.41)

0.266

1.06 (0.40, 2.82)

0.902a

0.97 (0.35, 2.68)

0.959

 Per 0.1 mmol/L increase

0.98 (0.93, 1.03)

0.368

1.02 (0.95, 1.09)

0.551a

1.01 (0.94, 1.10)

0.743

All-cause mortality

 Low HDL-C

1.94 (1.17, 3.20)

0.010

2.21 (1.13, 4.35)

0.021b

2.16 (1.06, 4.40)

0.033

 Intermediate HDL-C

Ref

–

Ref

–

Ref

–

 High HDL-C

0.51 (0.19, 1.35)

0.172

0.58 (0.16, 2.10)

0.406b

0.62 (0.17, 2.26)

0.464

 Per 0.1 mmol/L increase

0.90 (0.85, 0.95)

<0.001

0.88 (0.82, 0.95)

0.001b

0.88 (0.81, 0.96)

0.005

  1. Note: Model 1 Adjusted for age and gender. Model 2: aAdjusted for age, gender, disease duration, weight, eGFR, 24-h proteinuria, hypertension and lipid-lowering therapy. bAdjusted for age, gender, disease duration, weight, eGFR and hypertension. Model 3 Adjusted for age, gender, weight, eGFR, smoking status, SLEDAI, 24-h proteinuria, total cholesterol, triglyceride, LDL-C, diabetes mellitus, hypertension, hypoalbuminemia, disease duration, lipid-lowering therapy and immunosuppressive treatment
  2. HR hazard ratio; 95% CI 95% confidence interval